These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30171982)

  • 21. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
    Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting breast cancer stem cells by novel HDAC3-selective inhibitors.
    Hsieh HY; Chuang HC; Shen FH; Detroja K; Hsin LW; Chen CS
    Eur J Med Chem; 2017 Nov; 140():42-51. PubMed ID: 28923385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
    Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
    Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells.
    Yang L; Liang Q; Shen K; Ma L; An N; Deng W; Fei Z; Liu J
    Biomed Pharmacother; 2015 Apr; 71():70-8. PubMed ID: 25960218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy.
    Ganai SA
    Curr Top Med Chem; 2016; 16(22):2441-52. PubMed ID: 26873193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway.
    Tang S; Cheng B; Zhe N; Ma D; Xu J; Li X; Guo Y; Wu W; Wang J
    Anticancer Drugs; 2018 Jan; 29(1):61-74. PubMed ID: 29049036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
    Cai J; Wei H; Hong KH; Wu X; Zong X; Cao M; Wang P; Li L; Sun C; Chen B; Zhou G; Chen J; Ji M
    Bioorg Med Chem; 2015 Jul; 23(13):3457-71. PubMed ID: 25953722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
    Li X; Zhang Y; Jiang Y; Wu J; Inks ES; Chou CJ; Gao S; Hou J; Ding Q; Li J; Wang X; Huang Y; Xu W
    Eur J Med Chem; 2017 Jul; 134():185-206. PubMed ID: 28415009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents.
    Wang T; Sepulveda M; Gonzales P; Gately S
    Bioorg Med Chem Lett; 2013 Sep; 23(17):4790-3. PubMed ID: 23906422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
    Ojha R; Huang HL; HuangFu WC; Wu YW; Nepali K; Lai MJ; Su CJ; Sung TY; Chen YL; Pan SL; Liou JP
    Eur J Med Chem; 2018 Apr; 150():667-677. PubMed ID: 29567459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
    Li X; Hou J; Li X; Jiang Y; Liu X; Mu W; Jin Y; Zhang Y; Xu W
    Eur J Med Chem; 2015 Jan; 89():628-37. PubMed ID: 25462271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity.
    Xie R; Li Y; Tang P; Yuan Q
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4415-4420. PubMed ID: 28818449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Yang W; Li L; Ji X; Wu X; Su M; Sheng L; Zang Y; Li J; Liu H
    Bioorg Med Chem; 2014 Nov; 22(21):6146-55. PubMed ID: 25261927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
    Ling Y; Guo J; Yang Q; Zhu P; Miao J; Gao W; Peng Y; Yang J; Xu K; Xiong B; Liu G; Tao J; Luo L; Zhu Q; Zhang Y
    Eur J Med Chem; 2018 Jan; 144():398-409. PubMed ID: 29288941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel inhibitors of human histone deacetylases: design, synthesis and bioactivity of 3-alkenoylcoumarines.
    Seidel C; Schnekenburger M; Zwergel C; Gaascht F; Mai A; Dicato M; Kirsch G; Valente S; Diederich M
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3797-801. PubMed ID: 25042254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Largazole Analogues as Histone Deacetylase Inhibitors and Anticancer Agents: An Overview of Structure-Activity Relationships.
    Poli G; Di Fabio R; Ferrante L; Summa V; Botta M
    ChemMedChem; 2017 Dec; 12(23):1917-1926. PubMed ID: 29117473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
    Chen C; Hou X; Wang G; Pan W; Yang X; Zhang Y; Fang H
    Eur J Med Chem; 2017 Jun; 133():11-23. PubMed ID: 28371677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of novel ferulic acid derivatives as potent histone deacetylase inhibitors.
    Wang F; Lu W; Zhang T; Dong J; Gao H; Li P; Wang S; Zhang J
    Bioorg Med Chem; 2013 Nov; 21(22):6973-80. PubMed ID: 24095016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
    Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
    ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
    Soumyanarayanan U; Ramanujulu PM; Mustafa N; Haider S; Fang Nee AH; Tong JX; Tan KSW; Chng WJ; Dymock BW
    Eur J Med Chem; 2019 Dec; 184():111755. PubMed ID: 31627059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.